Personalis (NASDAQ:PSNL) Stock Price Up 8.7% – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL)’s stock price rose 8.7% on Thursday . The company traded as high as $10.29 and last traded at $10.32. Approximately 1,043,793 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 1,726,333 shares. The stock had previously closed at $9.49.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. BTIG Research dropped their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Needham & Company LLC boosted their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Morgan Stanley dropped their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Performance

The company has a 50-day moving average of $6.86 and a 200-day moving average of $8.10. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -11.18 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. As a group, analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Insider Activity at Personalis

In related news, CEO Christopher M. Hall sold 80,091 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $11.02, for a total value of $882,602.82. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $2,600,565.72. The trade was a 25.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 38,799 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $11.58, for a total value of $449,292.42. Following the completion of the transaction, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,302,486.14. This represents a 16.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 138,799 shares of company stock valued at $1,551,292 over the last quarter. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Personalis

Several institutional investors and hedge funds have recently modified their holdings of PSNL. Royal Bank of Canada grew its position in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd grew its position in shares of Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after purchasing an additional 33,044 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after purchasing an additional 101,706 shares during the period. Focus Partners Wealth bought a new stake in Personalis in the 1st quarter valued at approximately $47,000. Finally, JPMorgan Chase & Co. lifted its stake in Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after acquiring an additional 24,621 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.